Abstract
The aim of this study was to investigate the psychometric properties of the Greek version of FACIT-COST, as well as to assess the levels of financial distress of patients suffering from lung cancer in relation to their quality of life and lung cancer symptom burden. This was a cross-sectional quantitative study. A self-assessment instrument was used to gather the data. The study involved 120 lung cancer patients who were treated using chemotherapy in a day clinic of a General Hospital in Athens. Data were collected with the COST-FACIT-v2 (used to assess the patients’ financial toxicity), The 12-item Health Survey (SF-12), and functional Assessment of Cancer Therapy—Lung Symptom Index Questionnaire—7 items—version 4 (FACIT—FACT-LCS). Descriptive statistics as well as exploratory factor analysis performed all the statistical analyses, which were conducted using IBM SPSS Statistics 25 and had p-values with a significance level of 0.05. The majority of the participants were male (68.3%), married or cohabitated (81.3%), and had been diagnosed with microcell cancer (90%). The factor analysis resulted in one factor that interpreted 35% of the total variance. FACT-L (r = 0.365, p < 0.001), physical component SF-12 (r = 0.184, p = 0.045), and mental health component SF-12 (r = 0.268, p = 0.003) were positively correlated to FACIT-OST, as expected. The Greek validated COST-FACIT-v2 is a reliable tool in providing rapid assessment of cancer patients’ level of financial distress.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Similar content being viewed by others
References
Deo SVS, Gowda SM, Bhoriwal S (2021) Epidemiology of cancer. In: Garg R, Bhatnagar S (eds) Textbook of onco-anesthesiology [Internet]. Springer, Singapore [cited 2021 Sep 16], pp 7–12. Available from https://doi.org/10.1007/978-981-16-0006-7_2
Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A et al (2021) Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 71(3):209–249
Ferlay J, Colombet M, Soerjomataram I, Parkin DM, Piñeros M, Znaor A et al (2021) Cancer statistics for the year 2020: an overview. Int J Cancer 149(4):778–789
Tsvetkova A, Mihaylova S, Kamusheva M (2021) Social and economic burden of breast cancer in the North East region of Bulgaria. Expert Rev Pharmacoecon Outcomes Res 0(0):1–7
Tur-Sinai A, Urban D, Bentur N (2021) Out-of-pocket spending of deceased cancer patients in five European countries and Israel. Eur J Cancer Care (Engl) 30(2):e13372
Goyanka R (2021) Economic and non-economic burden of cancer: a propensity score matched analysis using household health survey data of India. Cancer Res Stat Treat 4(1):29
Iragorri N, de Oliveira C, Fitzgerald N, Essue B (2021) The out-of-pocket cost burden of cancer care—a systematic literature review. Curr Oncol 28(2):1216–1248
Rezapour A, Nargesi S, Mezginejad F, Kemmak AR, Bagherzadeh R (2021) The economic burden of cancer in Iran during 1995-2019: a systematic review. Iran J Public Health 50(1):35–45
Lu L, Gavin A, Drummond FJ, Sharp L (2021) Cumulative financial stress as a potential risk factor for cancer-related fatigue among prostate cancer survivors. J Cancer Surviv 15(1):1–13
Salsman JM, Danhauer SC, Moore JB, Ip EH, McLouth LE, Nightingale CL et al (2021) Systematic review of financial burden assessment in cancer: evaluation of measures and utility among adolescents and young adults and caregivers. Cancer 127(11):1739–1748
Bygrave A, Whittaker K, Paul C, Fradgley EA, Varlow M, Aranda S (2021) Australian experiences of out-of-pocket costs and financial burden following a cancer diagnosis: a systematic review. Int J Environ Res Public Health 18(5):2422
Richard P, Patel N, Lu Y-C, Walker R, Younis M (2021) The financial burden of cancer on families in the United States. Int J Environ Res Public Health 18(7):3790
Bradley CJ, Yabroff KR, Zafar SY, Shih Y-CT (2021) Time to add screening for financial hardship as a quality measure? CA Cancer J Clin 71(2):100–106
Lee J, Cagle JG (2021) Measures of financial burden for families dealing with serious illness: a systematic review and analysis. Palliat Med 35(2):280–294
Durber K, Halkett GK, McMullen M, Nowak AK (2021) Measuring financial toxicity in Australian cancer patients—validation of the comprehensive score for financial toxicity (FACT COST) measuring financial toxicity in Australian cancer patients. Asia Pac J Clin Oncol 17(4):377–387
de Souza JA, Yap BJ, Wroblewski K, Blinder V, Araújo FS, Hlubocky FJ, Nicholas LH, O’Connor JM, Brockstein B, Ratain MJ, Daugherty CK, Cella D (2017) Measuring financial toxicity as a clinically relevant patient-reported outcome: the validation of the comprehensive score for financial toxicity (COST). Cancer 123(3):476–484. https://doi.org/10.1002/cncr.30369
Kontodimopoulos N, Pappa E, Niakas D, Tountas Y (2007) Validity of SF-12 summary scores in a Greek general population. Health Qual Life Outcomes 5:55. https://doi.org/10.1186/1477-7525-5-55
Yount S, Beaumont J, Rosenbloom S, Cella D, Patel J, Hensing T, Jacobsen PB, Syrjala K, Abernethy AP (2012) A brief symptom index for advanced lung cancer. Clin Lung Cancer 13(1):14–23. https://doi.org/10.1016/j.cllc.2011.03.033
Chan DNS, Choi KC, Ng MSN et al (2021) Translation and validation of the traditional Chinese version of the comprehensive score for financial toxicity-functional assessment of chronic illness therapy (version 2). Health Qual Life Outcomes 19:17. https://doi.org/10.1186/s12955-020-01646-z
Dar MA, Chauhan R, Sharma KK, Trivedi V, Dhingra S, Murti K (2021) Assessing the reliability and validity of comprehensive score for financial toxicity (COST) among radiation oncology patients in India: a cross-sectional pilot study. Ecancermed Sci 15:1219. https://doi.org/10.3332/ecancer.2021.1219
Robin Yabroff K, Mariotto A, Tangka F, Zhao J, Islami F, Sung H, Sherman RL, Henley SJ, Jemal A, Ward EM (2021) Annual report to the nation on the status of cancer, part 2: patient economic burden associated with cancer care. JNCI: J Natl Cancer Inst 113(12):1670–1682. https://doi.org/10.1093/jnci/djab192
Ezeife DA, Morganstein BJ, Lau S, Law JH, Le LW, Bredle J, Cella D, Doherty MK, Bradbury P, Liu G, Sacher A (2019) Financial burden among patients with lung cancer in a publically funded health care system. Clin Lung Cancer 20(4):231–236
Chen JE, Lou VW, Jian H, Zhou Z, Yan M, Zhu J, Li G, He Y (2018) Objective and subjective financial burden and its associations with health-related quality of life among lung cancer patients. Support Care Cancer 26(4):1265–1272
Zafar SY, McNeil RB, Thomas CM, Lathan CS, Ayanian JZ, Provenzale D (2015) Population-based assessment of cancer survivors’ financial burden and quality of life: a prospective cohort study. J Oncol Pract 11(2):145–150
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2023 The Author(s), under exclusive license to Springer Nature Switzerland AG
About this paper
Cite this paper
Fradelos, E.C. et al. (2023). The Validation of the COmprehensive Score for Financial Toxicity (COST) Scale in Greek Language. In: Vlamos, P. (eds) GeNeDis 2022. GeNeDis 2022. Advances in Experimental Medicine and Biology, vol 1425. Springer, Cham. https://doi.org/10.1007/978-3-031-31986-0_18
Download citation
DOI: https://doi.org/10.1007/978-3-031-31986-0_18
Published:
Publisher Name: Springer, Cham
Print ISBN: 978-3-031-31985-3
Online ISBN: 978-3-031-31986-0
eBook Packages: Biomedical and Life SciencesBiomedical and Life Sciences (R0)